Keywords
How to Cite
Abstract
The role of radiotherapy in the treatment of lymphoproliferative disorders has evolved over time, particularly with the advent of effective immunochemotherapy regimens and, more recently, with the assessment of response using metabolic imaging techniques, such as positron emission tomography (PET). In the case of diffuse large B-cell lymphoma, this review examines the evidence regarding the usefulness of radiotherapy in localized stages, advanced stages with large masses, and some primary extranodal lymphomas, such as primary testicular and primary mediastinal lymphomas. It also considers the usefulness of radiotherapy in relapsed/refractory patients, either as a bridge to CAR-T therapy or for consolidation after autologous transplantation. Finally, the role of radiotherapy for palliative purposes.
References
Kaplan HS, Stewart JR. Complications of intensive megavoltage radiotherapy for Hodgkin's disease. Natl Cancer Inst Monogr 1973 May:36:439-44.
National Comprehensive Cancer Network. NCCN Guidelines: B-Cell Lymphomas v3.2022. Available at https://www.nccn.org/professionals/physician_ gls/pdf/b-cell.pdf. Accessed May 18, 2022.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin´s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin´s Lymphoma Classification Project. J Clin. Oncol 1998; 16: 2780-95.
Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large B-cell lymphomas. N Engl J Med 2008: 359: 2313-23.
Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d´Etude des Lymphomes de l´Adulte. J Clin Oncol 2005; 23: 4117-26.
Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus alone or with maintenance rituximab in older patients with diffuse large B cell lymphoma. H Clin. Oncol 2006; 24: 3121-7.
Lee BJ, Griffin SP, Doh J et al. R-DA-EPOCH vs DA-EPOCH-R. Impact of Chemoimmunotherapy sequencing on treatment outcomes in patients with Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2025; 25 (12): e1014-e1021.
Tilly H, Morschhauser F, Sehn L et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Eng J Med 2022; 386: 351-363.
Dabaja B, Phan J, Mawlawi O et al. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 2013; 54 (12): 2631-38.
Al-Mansour M, Al-Foheidi M, Ibrahim E. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B cell lymphoma: a meta-analysis. Mol Clin Oncol 2020; 13 (4): 1-4.
Thieblemont C, Karimi Y, Ghesquieres H et al. Epcoritamab in relapsed/refractory large B cell lymhoma: 2 year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 2024; 38: 2653-2662.
Dickinson M, Carlo Stella C, Morschhauser F et al. Glofitamab for Relapsed or Refractory Diffuse Large B cell Lymphoma. N Engl J Med 2022; 387: 2220-2231.
Kaminski MS, Coleman CN, Colby TV et al. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986; 104 (6): 747-756. doi:10.7326/0003-4819-104-6-747
Vaughan Hudson B, Vaughan Hudson G, Mac Lennan KA et al. Clinical stage 1 non-Hodgkin´s lymphoma: long term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69 (6): 1088-1093. doi:10.1038/bjc.1994.213
Kelsey CR, Beaven AW, Diehl LF. Radiation therapy in the management of Diffuse Large B-Cell Lymphoma: Still Relevant?. Oncology 2010; 24 (13): 1204-1212.
Horning SJ, Weller E, Kim K et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin´s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032-8. doi:10.1200/JCO.2004.06.088
Miller TP, Dahlberg S, Cassay JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin´s lymphoma. N Eng J Med 1998; 339: 21-6. doi:10.1056/NEJM199807023390104
Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy in limited-stage diffuse aggressive lymhoma in elderly patients: a study by the Groupe d´Etude des Lymphomes de l´Adulte. J Clin Oncol 2007; 25: 787-92.
Jones G, Plastaras JP, Ng AK. The evolving role of radiation therapy in DLBCL: from early-stage to refractory disease. Oncology 2022; 36 (12): 718-27. doi: 10.46883/2022.25920980
Lamy T, Damaj G, Soubeyran P et al. LYSA Group. R-CHOP with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 2018; 131 (2): 174-181.
Poeschel V, Held G, Zierpert M et al. FLYER Trial Investigators; German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomized, phase 3, non-inferiority trial. Lancet 2019; 394 (10216): 2271-2281.
Persky DO, Li H, Stephens DM, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38(26):3003-3011. doi:10.1200/JCO.2007.13.6929.
Sehn LH, Savage KJ, Hoskins P, et al. Limited-stage Diffuse Large B-cell Lymphoma (DLBCL) patients with a negative PET Scan following three cycles of R-CHOP can be effectively treated with abbreviate chemoimmunotherapy alone. Blood 2007; 110 (11): 787-796. Doi: 10.1182/blood.V110.11.787.787.
Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381(9880):1817-1826. doi:10.1016/S0140-6736(13)60313-X.
Bartlett NL, Wilson WH, Jung S-H, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799. doi:10.1200/JCO.18.01994
Ferreri AJ, Dell’Oro S, Reni M, et al. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology 2000;58(3):219-226. doi:10.1159/000012104
Pfreundschuh M, Schubert K, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP14 with or without rituximab in elderly patients with aggressive CD 20+ B-cell lymphoma: a randomized controlled trial (RICOVER 60). Lancet Oncol 2008; 9(2): 105-116. Doi: 10.1016/S1470-2045(08)70002-0
Pfreundschuh M, Murawski N, Ziepert M, et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J Clin Oncol. 2017;36(Suppl 15):7574. doi:10.1200/JCO.2018.36.15_suppl.7574.
Freeman CL, Savage KJ, Villa DR, et al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021;137(7):929-938. doi:10.1182/blood.2020005846
Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115-4122. doi:10.1200/JCO.2012.48.0467
Martelli M, Ceriani L, Ciccone G et al. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. J Clin Oncol 2024; 42 (34): 4071-4083. Doi: 10.1200/JCO-24-01373.
Savage KJ, Al-Rajhi N, Voss N et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17 (1): 123.30. dou: 10.1093/annonc/mdj030.
Renaud L, Donzel M, Decroocq J et al. Primary mediastinal B-cell lymphoma (PMBCL): Te LYSA pragmatic guidelines. Eur J Cancer 2025; 220: 1-19. Doi.org/10.1016/j.ejca.2025.115369.
Castellino A, Vitolo U. The management and treatment of primary testicular lymphoma. Hematology 2014; 8: 123-132.
Vitolo U, Chiappella A, Ferreri AJM, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766- 72.
Pinnix CC, Gunther JR, Dabaja BS, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv2020;4(13):2871-2883. doi:10.1182/bloodadvances.2020001837.
Wright CM, LaRiviere MJ, Baron JA, et al. Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2020;108(1):178-188. doi:10.1016/j.ijrobp.2020.05.014.
Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1987;316(24):1493-1498. doi:10.1056/NEJM198706113162401.
Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652-669. doi:10.1016/j.ijrobp.2017.12.005.
Wright CM, Koroulakis AI, Baron JA, et al. Palliative radiotherapy for diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(10):650-658. doi:10.1016/j.clml.2021.05.007.
Wright CM, Mendes A, Maxwell RJL, et al. Local control and response rates following hypofractionated palliative radiotherapy for relapsed/refractory diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2020;108(3 Suppl):E754. doi:10.1016/j.ijrobp.2020.07.177
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2026 Marta Zerga